Patent classifications
C
CHEMISTRY; METALLURGY
Load children
C07
ORGANIC CHEMISTRY
Load children
C07F
ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
Load children
9/00
Compounds containing elements of Groups 5 or 15 of the Periodic Table
Load children Filter patents View analytics View as hierarchy Open in page
C07F9/547
Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
Load children Filter patents View analytics View as hierarchy Open in page
C07F9/6553
having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
Load children Filter patents View analytics View as hierarchy Open in page
C07F9/655381
the sulfur atom being part of a seven-(or more) membered ring
Load children Filter patents View analytics View as hierarchy Open in page
C07F9/65539
condensed with carbocyclic rings or carbocyclic ring systems
Filter patents View analytics View as hierarchy Open in page

C07F9/65539

GPR84 RECEPTOR ANTAGONIST AND USE THEREOF
20200010492 · 2020-01-09 ·

The present invention relates to a GPR84 receptor antagonist and use thereof. The GPR84 receptor antagonist of the present invention has a structure as represented by formula (I), the definitions of R1, R2, R3, R4, L.sub.1, L.sub.2, L.sub.3, L.sub.4, L.sub.5, L.sub.6, Y, Z, and rings A, B, C, and D are as described in the description and claims. The GPR84 receptor antagonist of the present invention can competitively inhibit the activation of the receptor caused by an agonist of GPR84, and can be used in the preparation of a medicament for treating related diseases caused by high expression or high excitability of GPR84 receptor, the diseases including multiple sclerosis, inflammatory bowel disease, arthritis and the like.

##STR00001##

ASYMMETRIC GPR84 ANTAGONIST AND USE THEREOF
20240342201 · 2024-10-17 ·

An asymmetric GPR84 antagonist and a use thereof, the GPR84 antagonist having a structure as shown in formula I. The compound represented by formula I has GPR84 antagonistic activity, can competitively inhibit GPR84 agonist-induced receptor activation, and can be used to treat various diseases associated with the high expression or hyperexcitability of GPR84, such as multiple sclerosis, inflammatory bowel disease, organ fibrosis, arthritis, etc.

##STR00001##